Frazier Lifesciences Acquisition Q1 FY22: net income $1.4M, down 51%

Key figures from this report

These are the numbers Frazier Lifesciences Acquisition reported for Q1 FY22, the quarter ended Mar 31, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income$1.4M−51% from $2.8M in Q1 FY2110-Q income statement, on EDGAR
2. Cash and cash equivalents$788K−32% from $1.2M in Q1 FY2110-Q balance sheet, on EDGAR
3. Cash from operations−$394K−294% from $202K in Q1 FY2110-Q cash flow statement, on EDGAR